Zacks Investment Research·5 days ago
Here's Why Absci Corporation (ABSI) is a Great Momentum Stock to BuyDoes Absci Corporation (ABSI) have what it takes to be a top stock pick for momentum investors? Let's find out.
Absci Corporation(ABSI)Earnings, Financials & Key Ratios
ABSI•NASDAQ
$11.33
Price updated Jul 7, 2026
AboutAbsci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.Show more
- Revenue$3M-38.2%
- EBITDA-$113M-18.3%
- Net Income-$115M-11.7%
- EPS (Diluted)-0.84+10.6%
- Gross Margin-319.36%+75.0%
- EBITDA Margin-4034.86%-91.6%
- Operating Margin-4454.21%-85.5%
- Net Margin-4113.68%-80.9%
- ROE-62.5%-7.7%
ABSI Price & Volume
Absci Corporation (ABSI) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Threatens Operational Liquidity Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity exhaustion
Key Thesis Takeaways
- Absci faces a precarious fundamental outlook characterized by an 81.8% year-over-year revenue decline in 2026Q1 and a persistent inability to achieve positive gross margins, which stood at -11.7% in the same period.
- The company's reliance on non-recurring milestone payments creates extreme volatility, while the $30.8 million operating loss in 2026Q1 significantly outpaces its dwindling cash reserves.
- Investors should monitor the company's ability to secure non-dilutive capital, as the current $8.6 million cash position appears insufficient to sustain its high-fixed-cost R&D infrastructure.
Verdict Logic
the company's cash position of $8.6 million against a quarterly operating loss of $30.8 million suggests an imminent risk of liquidity exhaustion and potential shareholder dilution.
ABSI Growth Metrics
Absci Corporation (ABSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-10.14%
3 Years-21.31%
TTM-61.87%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-10.2%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM9.78%
Return on Capital
10 Years-43.31%
5 Years-47.17%
3 Years-57.54%
Last Year-65.9%
ABSI Recent Earnings
Absci Corporation (ABSI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 1/12 qtrs (8%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.19+5.0%
$0.20
Rev
$215,000-82.9%
$1M
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.23-43.8%
$0.16
Rev
$650,000-51.5%
$1M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.20-5.3%
$0.19
Rev
$378,000-72.6%
$1M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.24-26.3%
$0.19
Rev
$593,000-88.5%
$5M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.19vs $0.20+5.0% | $215,000vs $1M-82.9% |
| Q2 2026 | Mar 24, 2026 | $0.23vs $0.16-43.8% | $650,000vs $1M-51.5% |
| Q4 2025 | Nov 12, 2025 | $0.20vs $0.19-5.3% | $378,000vs $1M-72.6% |
| Q3 2025 | Aug 12, 2025 | $0.24vs $0.19-26.3% | $593,000vs $5M-88.5% |
Based on last 12 quarters of dataView full earnings history →
Latest ABSI News
Recent stock market news and headlines for Absci Corporation (ABSI)
Zacks Investment Research·Jun 25, 2026
ABSI Soars 36% on Positive Interim Update From Phase I Hair Loss StudyAbsci stock jumps 36% as interim phase I hair loss study data show ABS-201 is well tolerated and pharmacokinetics support the potential for infrequent dosing.
Zacks Investment Research·Jun 25, 2026
ABSCI CORP (ABSI) Soars 36.0%: Is Further Upside Left in the Stock?ABSCI CORP (ABSI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Benzinga·Jun 24, 2026
Absci Raises $100 Million In Equity To Fund AI-Designed Hair Loss And Endometriosis ProgramAbsci Corporation (NASDAQ:ABSI) stock is trading higher on Wednesday after the company reported positive interim Phase 1 results for its investigational anti-prolactin receptor antibody, ABS-201, while also pricing a $100 million underwritten stock offering to support continued development of the program.
GlobeNewsWire·Jun 24, 2026
Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial InvestorsEli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci
Peers Comparison
Key metrics vs top competitors for Absci Corporation (ABSI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $11.33 | $1.77B | -13.49 | -38.24% | -4113.68% | -62.5% | — | |
| $3.84 | $1.72B | -2.67 | 26.92% | -844.46% | -54.32% | — | |
| $16.49 | $1.23B | -11.70 | 23.29% | -40.6% | -30.85% | — | |
| $19.04 | $501.56M | -0.16 | -3% | -137.5% | -171.72% | — | |
| $91.03 | $5.67B | -70.02 | 20.32% | -19.85% | -17.46% | — | |
| $37.92 | $3.9B | -46.81 | 120.01% | -49.17% | -5.89% | — |
Compare ABSI vs Peers
Absci Corporation (ABSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ABSI SEC Filings & Documents
Absci Corporation (ABSI) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Mar 6, 2026·SEC
10-K Annual Reports
410-Q Quarterly Reports
6Get notified when ABSI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ABSI Frequently Asked Questions
Absci Corporation (ABSI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Absci Corporation's revenue?
Absci Corporation (ABSI) reported $1.8M in revenue for fiscal year 2025. This represents a 11% decrease from $2.1M in 2019.
How fast is Absci Corporation growing?
Absci Corporation (ABSI) saw revenue decline by 38.2% over the past year.
Is ABSI profitable?
Absci Corporation (ABSI) reported a net loss of $118.4M for fiscal year 2025.
Dividend & Returns
What is ABSI's return on equity?
Absci Corporation (ABSI) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.
What is Absci Corporation's free cash flow?
Absci Corporation (ABSI) had negative free cash flow of $98.5M in fiscal year 2025, likely due to heavy capital investments.